Last updated on October 2018

Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification HER2 Mutation/Amplification HER3/4 Mutation or KRAS Mutation

Brief description of study


Primary Objectives:

To evaluate the safety and tolerability of neratinib when combined with one of the following


Arm 1: Everolimus (mTOR inhibitor) Arm 2: Palbociclib (CDK 4/6 inhibitor) Arm 3: Trametinib (MEK inhibitor) To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of neratinib combination therapy.

Secondary Objectives:

To determine preliminary anti-tumor efficacy of neratinib combination therapy. To determine pharmacodynamic markers in tissue, blood and plasma that may predict outcome.

To explore the potential of drug-drug interactions by evaluating the pharmacokinetic profile of each agent when administered in these combinations: neratinib+everolimus, neratinib+palbociclib, and neratinib+trametinib and blood-based biomarkers.

Clinical Study Identifier: NCT03065387

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.